Publications
Publications
Show Results For
- All HBS Web
(1,288)
- Faculty Publications (518)
←
Page 26 of 518
Results
- October 1986 (Revised August 2015)
- Case
Advanced Medical Technology Corporation
By: Thomas R. Piper and Steven Rogers
A loan officer must decide whether to lend $8 million to a rapidly growing high technology company. The company has had a series of relationships with three other banks. Reports from loan officers at these banks are mixed and raise questions as to the ease with which a... View Details
- December 1985 (Revised July 1992)
- Case
Pennsylvania Pharmaceuticals (A)
By: Michael Beer
Keywords: Pharmaceutical Industry
- October 1982 (Revised May 1992)
- Case
Johnson & Johnson: The Tylenol Tragedy
In October 1982, Johnson & Johnson was confronted with a major crisis when seven deaths were attributed to poisoned Tylenol. The case reviews the facts as known a week after the incident occurred, and raises a wide range of questions regarding consumer behavior,... View Details
- July 1981 (Revised December 1984)
- Case
American Distilling Co. (A)
- July 1981 (Revised December 1984)
- Case
American Distilling Co. (B)
- October 1976 (Revised June 1980)
- Case
Dana Pharmaceutical
By: Thomas R. Piper
Keywords: Pharmaceutical Industry
- February 1974
- Case
Listerine Lozenges
- February 1973 (Revised June 1973)
- Case
Listerine Antiseptic (A)
- Research Summary
AIDS in Africa: Life, Death and Property Rights
By: Debora L. Spar
In the final years of the twentieth century, the world was hit by a plague of epidemic proportions--the plague of AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought... View Details
- 2018
- Chapter
Are Licensing Markets Local? An Analysis of the Geography of Vertical Licensing Agreements in Bio-Pharmaceuticals
By: Juan Alcacer, John Cantwell and Michelle Gittelman
As the value chain of the pharmaceutical industry disaggregates, upstream discovery is increasingly carried out by small research-specialized firms while downstream development, testing and marketing is conducted by global pharmaceutical firms. Licensing plays an... View Details
- Research Summary
Multinational Enterprises and Corporate Responsibility
By: Nien-he Hsieh
Multinational enterprises, especially those operating in developing economies, face wide-ranging demands to help persons whose basic needs are unmet. Pharmaceutical companies, for example, are asked to provide access to life-saving therapies to patients in countries... View Details
- Research Summary
Overview
By: Kyle R. Myers
Professor Myers studies the economics of what determines the rate and direction of innovation. He has examined the reallocation of scientists through the use of targeted research grants at the National Institutes of Health, and is working to further understand how... View Details
Keywords: Technology Networks; Commercialization; Science-Based Business; Research and Development; Knowledge Management; Patents; Innovation Strategy; Technological Innovation; Health Care and Treatment; Entrepreneurship; Health; Innovation and Invention; Science; Technology; Knowledge; Intellectual Property; Economics; Microeconomics; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
- Research Summary
Overview
By: Andy Wu
How can technology entrepreneurs build competitive advantage from the ground up? Professor Andy Wu conducts scholarly research and develops course materials that document how technology entrepreneurs can (1) organize for innovation to create new market opportunities... View Details
Keywords: Strategy; Entrepreneurship; Venture Capital; Growth Management; Organizational Design; Organizational Structure; Technology Platform; Technological Innovation; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; China; Southeast Asia; South Asia
- Forthcoming
- Article
Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation
By: Amitabh Chandra, Jennifer Kao, Kathleen L. Miller and Ariel Dora Stern
Regulators of new products confront a tradeoff between speeding a product to market and collecting additional product quality information. The FDA's Breakthrough Therapy Designation (BTD) provides an opportunity to understand if regulators can use new policy to... View Details
- Research Summary
Research Summary
By: Leslie A. Perlow
There has been tremendous change in the workplace — ubiquitous technology, 24/7 globalization, hyper-efficiency and now significant changes in work location. Professor Perlow’s research explores the implications for the ways we work and live, and what we can do to... View Details
- ←
- 26